Chemistry:Ecnoglutide
From HandWiki
Ecnoglutide (XW003) is a GLP-1 agonist being developed for the treatment of obesity and type 2 diabetes.[1][2][3] In preclinical trials, "Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process" compared to other GLP-1 agonist lipopeptides.[4]
A phase 3 trial published in 2025 showed 9-13% reduction in bodyweight versus placebo over a 48 week treatment, varying by ecnoglutide dose.[5][6]
In January 2026, ecnoglutide injection is approved for marketing in China.[7]
References
- ↑ Wang, Guang; Hu, Wei; Qin, Hong H.; Zheng, Qing; Ning, Jing; Mengying, Guo; Bu, Yue; Jones, Catherine et al. (20 June 2023). "756-P: A Phase 1c Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Weight Loss in Adults with Overweight and Obesity". Diabetes 72 (Supplement_1). doi:10.2337/db23-756-P.
- ↑ Guo, Wanjun; Xu, Zheng; Zou, Haixia; Li, Feng; Li, Yao; Feng, Jing; Zhu, Zhiyi; Zheng, Qing et al. (September 2023). "Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog". Molecular Metabolism 75. doi:10.1016/j.molmet.2023.101762. PMID 37364710.
- ↑ Zhu, Dalong; Qin, Hong H.; Zheng, Qing; Ning, Jing; Zhu, Zhiyi; Mengying, Guo; Bu, Yue; Jones, Catherine et al. (20 June 2023). "755-P: A Phase 2 Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Glycemic Control in Adults with Type 2 Diabetes". Diabetes 72 (Supplement_1). doi:10.2337/db23-755-P.
- ↑ Guo, Wanjun; Xu, Zheng; Zou, Haixia; Li, Feng; Li, Yao; Feng, Jing; Zhu, Zhiyi; Zheng, Qing et al. (September 2023). "Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog". Molecular Metabolism 75. doi:10.1016/j.molmet.2023.101762. ISSN 2212-8778. PMID 37364710.
- ↑ , Wikidata Q135181658
- ↑ , Wikidata Q135181659
- ↑ "国家药监局批准埃诺格鲁肽注射液上市". 30 January 2026. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20260130142923121.html.
 |  |
